¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hyper-IgM Immunodeficiency Syndrome, Type 1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • Lesch-Nyhan syndrome
    ·¹½´-´ÏÇÑÁõÈıº
  • Libman-Sacks syndrome
    ¸®ºê¸Õ-»è½ºÁõÈıº
  • locked-in syndrome
    °¨±ÝÁõÈıº
  • long QT syndrome
    ±äQTÁõÈıº
  • lymphadenopathy syndrome
    ¸²ÇÁÀýº´(Áõ)ÁõÈıº
  • lymphoproliferative syndrome
    ¸²ÇÁ¼¼Æ÷Áõ½ÄÁõÈıº
  • middle lobe syndrome
    Áß°£¿±ÁõÈıº
  • milk-alkali syndrome
    ¿ìÀ¯¾ËÄ®¸®ÁõÈıº
  • morning glory syndrome
    ³ªÆÈ²ÉÁõÈıº
  • motor syndrome
    ¿îµ¿(ÁßÃß)ÁõÈıº
  • mucocutaneous lymph node syndrome
    Á¡¾×ÇǺθ²ÇÁÀýÁõÈıº
  • myasthenic syndrome
    ±Ù(À°)¹«·ÂÁõÈıº
  • Mallory-Weiss syndrome
    ¸»·Î¸®-¹ÙÀ̽ºÁõÈıº
  • myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • myeloproliferative syndrome
    °ñ¼öÁõ½ÄÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • maltreatment syndrome
    ÇдëÁõÈıº
  • maternal deprivation syndrome
    ¸ð¼º¹ÚÅ»ÁõÈıº
  • megacystis-megaureter syndrome
    Å«¹æ±¤Å«¿ä°üÁõÈıº
  • meningeal irritation syndrome
    ¼ö¸·ÀÚ±ØÁõÈıº
  • midsystolic click syndrome
    ¼öÃàÁß±âŬ¸¯ÁõÈıº
  • morning glory syndrome
    ³ªÆÈ²ÉÁõÈıº
  • motor syndrome
    ¿îµ¿ÁßÃßÁõÈıº
  • myasthenic syndrome
    ±ÙÀ°¹«·ÂÁõÈıº
  • myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • myeloproliferative syndrome
    °ñ¼öÁõ½ÄÁõÈıº
  • myofascial click pain syndrome
    ±Ù¸·ÅëÁõÁõÈıº
  • myotonic syndrome
    ±ÙÀ°±äÀåÁõÈıº
  • naviculocapitate syndrome
    ¼Õ¹è¾Ë¸Ó¸®»ÀÁõÈıº
  • nephrotic syndrome
    ÄáÆÏÁõÈıº
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • Hallerman Streiff syndrome
    ÇÒ·¯¸¸-½ºÆ®¶óÀÌÇÁÁõÈıº.
  • Hallzouns syndrome
    ȦÁ¸ÁõÈıº
  • Hamman Rich syndrome =diffuse interstitial pulmonary fibrosis
    ÇØ¸Õ- ¸®Ä¡ÁõÈıº.
  • Hamman-Rich syndrome
    ÇØ¸Õ-¸®Ä¡ ÁõÈıº
  • Heerfordts syndrome => uveoparotid fever
    Ç츣Æ÷¸£Æ® ÁõÈıº
  • Henoch Schoenlein syndrome
    Çì³ëÈ£-½¨¶óÀÎÁõÈıº.
  • Henoch Schoenlein syndrome
    Çì³ëÈ£-½¨¶óÀÎÁõÈıº
  • Hermansky-Pudlak syndrome
    Ç츣¸¸½ºÅ°-Ǫµé¶óÅ© ÁõÈıº
  • Hermansky-Pudlak syndrome => oculocutaneous albinism
    ¾È±¸ ÇǺΠ¹é»öÁõ
  • Hoffmann s syndrome
    È£ÇÁ¸¸ÁõÈıº.
  • Holt Oram syndrome
    ȦƮ-¿À¶÷ÁõÈıº.
  • Horners syndrome
    È£³Ê ÁõÈıº
  • Horners syndrome
    È£³Ê¾¾ ÁõÈıº
  • Horners syndrome
    È£¸£³ÊÁõÈıº
  • Hunters syndrome => mucopolysaccharidosis
    ÇåÅÍ ÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • specific type
    ÇüƯÀ̼º(úþ÷åì¶àõ)
  • spectral type
    ½ºÆåÆ®·³Çü(¡­úþ).
  • spinal type
    ô¼öÇü(ô±âÐúþ).
  • split electrode type probe
    ºÐÇÒ Àü±Ø ŽÃËÀÚ
  • split-electrode-type probe
    ºÐÇÒ Àü±Ø ŽÃËÀÚ (ÝÂùÜ ï³Ð¿ ÷®õºí­)
  • sthenic type
    ±Ù·ÂÇü(ÐÉæ³úþ).
  • storage-type
    ÃàÀûÇü
  • supporting cell [type ii glomus cell]
    ¹öÆÀ¼¼Æ÷
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü(äâìÔû¡ ÐÝή).
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü(¡­ÑÌíåúþ).
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü(¡­ÑÌíåúþ)
  • thinking type
    »ç°íÇü(ÞÖÍÅúþ).
  • triaxone type
    »ïÃàÇü(ß²õîúþ).
  • tuberculoid (type) leprosy
    À¯°áÇÙ³ª(׾̿ú·ÑÛ), °áÇپ糪(Ì¿ú·åÆÑÛ).
  • tuberculoid (type) leprosy
    À¯°áÇÙ³ª(׾̿ú·ÑÛ), °áÇپ糪(Ì¿ú·åÆ )
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
GS gallstone; Gardner syndrome; gastric shield; general surgery; gestational score; Gilbert syndrome; g...
HSS Hallermann-Streiff syndrome; Hallervorden-Spatz syndrome; Henoch-Schonlein syndrome; high-speed supe...
MAS magic angle spinning; Manifest Anxiety Scale; maximum average score; McCune-Albright syndrome; mecon...
MDS Master of Dental Surgery; maternal deprivation syndrome; medical data screening; medical data system...
OHS obesity hypoventilation syndrome; occipital Horn syndrome; occupational health service; ocular histo...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
ATII Alveolar type II
ATD Alzheimer Type Dementia
AD Alzheimer type dementia
A.T.C.C. American Type Culture Collection
AT1 Angiotensin II type 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cranial nerve syndrome
    ³ú½Å°æ ÁõÈıº
  • cri du chat syndrome
    ¹¦¼º ÁõÈıº
    Á¦ 5¹ø ¿°»öüÀÇ ´Ü¿ÏÀÇ ÀϺΰ¡ °á¼ÕµÇ¾î ³ªÅ¸³ª´Â À¯Àü¼º ¼±Ãµ¼º ÁõÈıºÀ¸·Î, ¾ç¾È °Ý¸®Áõ, ¼ÒµÎÁõ, ½ÉÇÑ Á¤½Å¹Ú¾àÁõ, °í¾çÀÌ °°Àº ¿ïÀ½¼Ò¸®¸¦ Ư¡À¸·Î ÇÑ´Ù.
  • Crigler-Najjar syndrome
    Å©¸®±Û·¯-³ª¾ß ÁõÈıº
  • Crouzon syndrome
    Å©·ÎÁ¸ ÁõÈıº, Å©·çÁ¸ ÁõÈıº
    µÎ°³ ¾È¸é À̰ñÁõ, Å©·çÁ¸¾¾ Áúȯ, ¿¡ÆÛÆ® Å©·çÁ¸¾¾ ÁõÈıº µîÀÌ µ¿ÀǾî·Î ¾²À̰í ÀÖ´Ù. µÎ°³ ±âÇü, ¾È¸é Áß¾ÓºÎÀÇ Çü¼º ºÎÀü ¹× ¾èÀº ¾È¿Í·Î ÀÎÇÑ ¾È±¸ µ¹ÃâÁõÀ» Ư¡À¸·Î ÇÑ´Ù.
  • CRST syndrome
    CRST ÁõÈıº
    Calcinosis, Raynauds
  • Cushing's syndrome
    Äí½Ì ÁõÈıº
    1. ºÎ½Å ÇÇÁúÀÇ Á¾¾ç ¶Ç´Â °úÇÕ¼º¿¡ ÀÇÇØ ÄÚ¸£Æ¼Á¹ÀÌ Áö³ªÄ¡°Ô ºÐºñµÊÀ¸·Î½á »ý±ä´Ù. º¸¸§´Þ°ú °°Àº ¾ó±¼ ¸ð½À, ¾È¸é È«Á¶, ÆÄÆÈ·ÎÇü ºñ¸¸, ¼±Ãµ¼º ÇǺμ±¿°, °íÇ÷¾Ð µîÀÌ Æ¯Â¡ÀÖ´Â Áõ»óÀÌ´Ù. 2. ºÎ½Å ÇÇÁú¿¡¼­ ´çÁú ÄÚ¸£Æ¼ÄÚÀ̵尡 °ú´ÙÇÏ°Ô ºÐºñµÇ´Â º´. 1932³â ¹Ì±¹ÀÇ H. Äí½ÌÀÌ ¹ß°ßÇÏ¿´´Ù. ºÎ½Å ÇÇÁú¿¡ ¾Ç¼º ¶Ç´Â ¾ç¼ºÀÇ Á¾¾çÀÌ »ý±â°Å³ª ºÎ½Å ÇÇÁú ±× ÀÚü°¡ °ú´ÙÇÏ°Ô Áõ½ÄÇÏ´Â °æ¿ì¿¡ ³ªÅ¸³­´Ù. ºñ±³Àû µå¹® Áõ»óÀ¸·Î, 10¡­20´ë¿¡ ¸¹°í ¿©ÀÚ¿¡°Ô ¸¹´Ù. Áõ¼¼·Î´Â °íÇ÷¾Ð, ¸¸¿ù»ó ¾È¸ð
  • Cushingoid syndrome
    Äí½Ì¾ç ÁõÈıº
  • cystic duct syndrome
    ´ã³¶ °ü ÁõÈıº
  • de Clerambault syndrome
    ²ô·¹¶ûº¸¿À ÁõÈıº
  • de-toni-Debre-Fanconi syndrome
    µð-Åä´Ï-µðºê¸®-ÆÇÄÚ´Ï ÁõÈıº
  • Defibrillation syndrome
    Å»¼¶À¯¼Ò ÁõÈıº
  • deficient antibody syndrome
    Ç×ü °áÇÌ ÁõÈıº
  • deficit syndrome
    °áÇÌ ÁõÈıº
  • Demons-Meigs' syndrome
    µ¥¸ó½º-¸Þ±×½º ÁõÈıº
    ³­¼Ò ¼¶À¯Á¾À¸·Î È÷½ºÅ¸¹Î¿¡ ÀÇÇÑ ¾Æ³ªÇʶô½Ã Áõ»ó. ¼ö´ë»ç¿Í ±³Áú°èÀÇ º´º¯ ¹× Á¾¾çÀÇ È£¸£¸ó ÀÛ¿ë¿¡ ÀÇÇØ º¹¼ö¿Í Èä¼ö°¡ º´¹ßÇÑ´Ù.
  • denial-of-deficit syndrome
    °áÇÌ ºÎÁ¤ ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
type III hyperlipoproteinaemia <biochemistry> An inherited disorder (gene defect) where both cholesterol and triglycerides are elevated in the same patient. This condition accelerates the effects of atherosclerosis and thus increases the risk of cardiovascular disease. Conditions such as hypothyroidism, obesity and diabetes enhances this risk.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III hypersensitivity reaction An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis.
See: autoimmune disease.
Synonym: immune complex disorder, type III hypersensitivity reaction.
(05 Mar 2000)
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
type IV acrocephalosyndactyly Acrocephalosyndactyly with pointed nose, hypertelorism, cleft palate, congenital heart disease and pseudohermaphroditism; contractures of elbows and knees; soft tissue syndactyly, absent first metatarsal and great toe. Autosomal recessive.
(05 Mar 2000)
type IV collagen A less distinctly fibrillar form of collagen characteristic of basement membranes.
(05 Mar 2000)
type IV familial hyperlipoproteinaemia Plasma levels of VLDL, pre-beta-lipoproteins and triglycerides are increased on a normal diet, but beta-lipoproteins, cholesterol, and phospholipids are normal; hypertriglyceridemia is induced by a high carbohydrate diet; may be accompanied by abnormal glucose tolerance and susceptibility to ischemic heart disease; probably autosomal recessive inheritance.
Synonym: carbohydrate-induced hyperlipaemia, familial hyperprebetalipoproteinaemia, familial hypertriglyceridemia.
(05 Mar 2000)
type IV prepilin peptidase <enzyme> Product of the pulc-o pullulanase secretion gene operon; involved in processing prepilin signal peptide; may also function as an n-methyltransferase
Registry number: EC 3.4.99.-
Synonym: pulo protein, pulo gene product, pulo peptidase
(26 Jun 1999)
type locality <zoology> The geographical location of the occurrence of the population from which the type specimen was taken. Population occurring at type locality = topotypical population. Specimens collected at type locality = topotypes.
(09 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
ÅëÇÕ°Ë»ö ¿Ï·á